AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21538678 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet insomnia intervention (n = 14)
Number of subjects: 28
Study 21538678 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (n = 14)
Number of subjects: 28
Study 20121770 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.11 ml.mm(‐2) cross‐sectional nerve area with mepivacaine 1% (low volume)
Number of subjects: 10
Study 20121770 — intervention group
Group type: COMPARATOR
Intervention: 0.4 ml.mm(‐2) cross‐sectional nerve area with mepivacaine 1% (high volume)
Number of subjects: 10
Study 17505917 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention for HIV prevention
Number of subjects: 149
Study 17505917 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 149
Study 16181932 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (12 weeks, 2 times a week, 1 set of 8 to 12 repetitions at 40% to 60% of maximal lifts, progressed to 60% to 80%)
Number of subjects: 29
Study 16181932 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-listed for exercise)
Number of subjects: 29
Study 11978714 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed questionnaire about erectile dysfunction (ED) sent to the study population.
Number of subjects: 205
Study 11978714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no questionnaire sent).
Number of subjects: 205
Study 11978714 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed questionnaire about ED.
Number of subjects: 205
Study 11978714 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation with family doctor after questionnaire.
Number of subjects: 205
Study 10478149 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA with manufacturer recommended cutoff (CO)
Number of subjects: 277
Study 10478149 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA with increased cutoff value (2CO)
Number of subjects: 277
Study 8942514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin levels in the highest quartile at 26 weeks
Number of subjects: 580
Study 8942514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin levels in the highest quartile at 19 weeks
Number of subjects: 580
Study 8942514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin levels in the highest quartile at 36 weeks
Number of subjects: 580
Study 8942514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin levels in the highest quartile
Number of subjects: 580
Study 10145587 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function tests from 13 laboratories
Number of subjects: 5
Study 6121043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of lorazepam (2 mg)
Number of subjects: 10
Study 6121043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of lorazepam (2 mg)
Number of subjects: 10
Study 6121043 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lorazepam (2 mg)
Number of subjects: 10
Study 6121043 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual lorazepam (2 mg) from oral tablets
Number of subjects: 10
Study 6121043 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual lorazepam (2 mg) from specially formulated tablets
Number of subjects: 10
Study 6121043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular, oral, and sublingual lorazepam (2 mg)
Number of subjects: 10
Study 30666098 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids and auditory training for 6 months
Number of subjects: 40
Study 30666098 — intervention group
Group type: COMPARATOR
Intervention: Hearing aids
Number of subjects: 40
Study 28925529 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic CPT (controlled P ET ,CO2)
Number of subjects: 15
Study 28925529 — intervention group
Group type: COMPARATOR
Intervention: Poikilocapnic CPT (uncontrolled P ET ,CO2)
Number of subjects: 15
Study 28925529 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic CPT
Number of subjects: 15
Study 28925529 — intervention group
Group type: COMPARATOR
Intervention: Poikilocapnic CPT
Number of subjects: 15
Study 25504269 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation for AF in patients with ASD
Number of subjects: 18
Study 25504269 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched subjects without ASD)
Number of subjects: 18
Study 25504269 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial diameter in non-recurrent patients
Number of subjects: 18
Study 25504269 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial diameter as a factor in arrhythmia recurrences
Number of subjects: 18
Study 24756903 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) therapy
Number of subjects: 68
Study 22381040 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAR
Number of subjects: 1656
Study 22381040 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 1656
Study 20802325 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate consent acceptance
Number of subjects: 104
Study 20802325 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate consent acceptance criteria
Number of subjects: 104
Study 20802325 — intervention group
Group type: EXPERIMENTAL
Intervention: Limits on research risks
Number of subjects: 104
Study 20802325 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk limits with potential benefit
Number of subjects: 104
Study 20802325 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedures to determine capacity
Number of subjects: 104
Study 20802325 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of independent monitors and proxies
Number of subjects: 104
Study 17445955 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16 vaccine (three-dose regimen)
Number of subjects: 50
Study 16226164 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy
Number of subjects: 2885
Study 16226164 — intervention group
Group type: COMPARATOR
Intervention: Standard statin therapy
Number of subjects: 2885
Study 12236023 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-LOT (90 mg coumarin and 540 mg troxerutin per day)
Number of subjects: 231
Study 12236023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 12236023 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-LOT
Number of subjects: 231
Study 10101819 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpedicular instrumentation
Number of subjects: 71
Study 10101819 — intervention group
Group type: COMPARATOR
Intervention: No transpedicular instrumentation (Control)
Number of subjects: 71
Study 7576400 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt intake (20 mmol sodium/day)
Number of subjects: 46
Study 7576400 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt intake (300 mmol sodium/day)
Number of subjects: 46
Study 7576400 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-sensitive subjects
Number of subjects: 46
Study 2405915 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin nasal spray administered q.i.d. from the first through the fifth ECT
Number of subjects: 33
Study 2405915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 7040659 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 20
Study 7040659 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 20
Study 7040659 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Acupuncture and Control)
Number of subjects: 20
Study 31287766 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing, Learning, and Living With Autism Group
Number of subjects: 17
Study 31287766 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control group
Number of subjects: 17
Study 28340901 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 0
Study 25406226 — intervention group
Group type: EXPERIMENTAL
Intervention: Written materials plus nicotine replacement therapy (NRT)
Number of subjects: 348
Study 25406226 — intervention group
Group type: COMPARATOR
Intervention: Materials, NRT, and couple-based counseling
Number of subjects: 348
Study 24942849 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated bolus delivery of 0.2% ropivacaine (4 mL) with PRN boluses (5 mL, lockout 30 min)
Number of subjects: 101
Study 24942849 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of 0.2% ropivacaine (4 mL/h) with PRN boluses (5 mL, lockout 30 min)
Number of subjects: 101
Study 17608575 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (surgical technique without vertical releasing incisions)
Number of subjects: 15
Study 17608575 — intervention group
Group type: COMPARATOR
Intervention: Control group (broader flap and vertical releasing incisions)
Number of subjects: 15
Study 17608575 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study 15220019 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost, 1 drop in the affected eye QD (evening)
Number of subjects: 229
Study 15220019 — intervention group
Group type: COMPARATOR
Intervention: Fixed-combination dorzolamide/timolol, 1 drop in the affected eye BID (morning and evening)
Number of subjects: 229
Study 10875904 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory‐motor coordination task with increasing coordination rates
Number of subjects: 0
Study 10875904 — intervention group
Group type: EXPERIMENTAL
Intervention: Evoked brain responses to acoustic tones and self‐initiated finger movements
Number of subjects: 0
Study 9353612 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrotherapy (H-Wave machine, pulse width 4 ms, 25-35 V, > or = 2 Hz, 30 min daily for 4 weeks)
Number of subjects: 31
Study 9353612 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 31
Study 9353612 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrotherapy (after sham treatment)
Number of subjects: 31
Study 8144852 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (750 mg orally at 08:00 h on day 1 and at 4 hourly intervals over a 24-h period)
Number of subjects: 6
Study 8144852 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (750 mg)
Number of subjects: 6
Study 8144852 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone (20 mg tablet)
Number of subjects: 6
Study 3018023 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of 250 micrograms Cosyntropin (ACTH‐(1‐24))
Number of subjects: 17
Study 3018023 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection of 250 micrograms Cosyntropin (ACTH‐(1‐24))
Number of subjects: 17
Study 31774626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal delivery of human umbilical cord Wharton's jelly mesenchymal stromal cells (500,000 cells per 20 μL)
Number of subjects: 0
Study 31774626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal delivery of human umbilical cord Wharton's jelly mesenchymal stromal cells
Number of subjects: 0
Study 30683494 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional anti-inflammatory treatment plus colchicine for 3 months
Number of subjects: 110
Study 30683494 — intervention group
Group type: COMPARATOR
Intervention: Conventional anti-inflammatory treatment only
Number of subjects: 110
Study 28818324 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing
Number of subjects: 68
Study 28818324 — intervention group
Group type: COMPARATOR
Intervention: Circular external fixator
Number of subjects: 68
Study 26181174 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (E+P) - 0.625 mg/d conjugated equine estrogens plus 2.5 mg/d medroxyprogesterone acetate
Number of subjects: 27347
Study 26181174 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen alone - 0.625 mg/d conjugated equine estrogens
Number of subjects: 27347
Study 24290869 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 29
Study 24290869 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 29
Study 22980306 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 1509
Study 22980306 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 1509
Study 19414982 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 29
Study 19414982 — intervention group
Group type: COMPARATOR
Intervention: Oral hypoglycemic agent (OHA)
Number of subjects: 29
Study 17379484 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (n=52)
Number of subjects: 131
Study 17379484 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (n=56)
Number of subjects: 131
Study 17379484 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=23)
Number of subjects: 131
Study 14737055 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF at 5 Kg/kg for established febrile neutropenia (Group A)
Number of subjects: 100
Study 14737055 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF at 263 Kg/day if ANC was 1500/microl or less (Group B)
Number of subjects: 100
Study 14737055 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Group A and Group B
Number of subjects: 100
Study 11720296 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular supervised training
Number of subjects: 63
Study 11720296 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitored training
Number of subjects: 63
Study 11720296 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 11720296 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training groups (supervised and self-monitored)
Number of subjects: 63
Study 9427202 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial Corticosteroid Group
Number of subjects: 215
Study 9427202 — intervention group
Group type: COMPARATOR
Intervention: No Corticosteroid Group
Number of subjects: 215
Study 9427202 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Corticosteroid Group
Number of subjects: 215
Study 9427202 — intervention group
Group type: COMPARATOR
Intervention: No/delayed Corticosteroid Group
Number of subjects: 215
Study 8032072 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose (0.4 mg/kg)
Number of subjects: 30
Study 8032072 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose (0.6 mg/kg)
Number of subjects: 30
Study 8032072 — intervention group
Group type: COMPARATOR
Intervention: Control (without urapidil)
Number of subjects: 30
Study 8032072 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including urapidil)
Number of subjects: 30
Study 3689065 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily) plus aspirin (650 mg four times daily)
Number of subjects: 43
Study 3689065 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin (650 mg four times daily)
Number of subjects: 43
Study 29482256 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone monotherapy
Number of subjects: 60
Study 29482256 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole (5mg and 10mg)
Number of subjects: 60
Study 29482256 — intervention group
Group type: COMPARATOR
Intervention: Control (Risperidone only)
Number of subjects: 60
Study 27302126 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP) 20 mL/kg intravenous
Number of subjects: 54
Study 27302126 — intervention group
Group type: COMPARATOR
Intervention: Prothrombin complex concentrate (PCC) 30 IU/kg intravenous
Number of subjects: 54
Study 27302126 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP
Number of subjects: 54
Study 27302126 — intervention group
Group type: COMPARATOR
Intervention: PCC
Number of subjects: 54
Study 24770624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 14
Study 24770624 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA
Number of subjects: 14
Study 24770624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MDMA and ethanol
Number of subjects: 14
Study 24770624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 22846237 — intervention group
Group type: EXPERIMENTAL
Intervention: Male partner's volume per setting for bars and parks or public places
Number of subjects: 1585
Study 22846237 — intervention group
Group type: EXPERIMENTAL
Intervention: Male's volume per setting for quiet evening at home
Number of subjects: 1585
Study 22846237 — intervention group
Group type: EXPERIMENTAL
Intervention: Female partner's volume for quiet evening at home
Number of subjects: 1585
Study 21261207 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine for cleansing the cord
Number of subjects: 29760
Study 18940711 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile touch intervention
Number of subjects: 44
Study 18940711 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (a rest hour)
Number of subjects: 44
Study 16161468 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexamed (0.1% chlorhexidine)
Number of subjects: 90
Study 16161468 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexoral (0.1% hexetidine)
Number of subjects: 90
Study 16161468 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control compound
Number of subjects: 90
Study 16161468 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between Chlorhexamed and Hexoral
Number of subjects: 90
Study 16161468 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Hexoral and Placebo
Number of subjects: 90
Study 14561111 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil
Number of subjects: 19
Study 14561111 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 10833037 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Number of subjects: 280
Study 10833037 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 280
Study 8890490 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct help (answers)
Number of subjects: 201
Study 8890490 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect help (hints)
Number of subjects: 201
Study 1617799 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine alone at 0-30 minutes
Number of subjects: 6
Study 1617799 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone at 0 minutes
Number of subjects: 6
Study 1617799 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine at 0-30 minutes and GHRH at 15 minutes
Number of subjects: 6
Study 1617799 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin at 0 minutes and arginine at 0-30 minutes
Number of subjects: 6
Study 6231316 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 0
Study 6231316 — intervention group
Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 0
Study 29364033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupping therapy (7-minute treatment with four 2-in cups on trigger points in hamstring)
Number of subjects: 25
Study 29364033 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study 30290680 — intervention group
Group type: EXPERIMENTAL
Intervention: early intensive BP lowering (systolic target range 140‐160 mm Hg)
Number of subjects: 54
Study 30290680 — intervention group
Group type: COMPARATOR
Intervention: guideline‐based BP management (systolic range 160‐180 mm Hg)
Number of subjects: 54
Study 30290680 — intervention group
Group type: EXPERIMENTAL
Intervention: not available
Number of subjects: 54
Study 26868520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral irradiation with 660 nm laser
Number of subjects: 60
Study 26868520 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraoral irradiation with 660 nm laser
Number of subjects: 60
Study 26868520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral irradiation with 808 nm laser
Number of subjects: 60
Study 26868520 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraoral irradiation with 808 nm laser
Number of subjects: 60
Study 26868520 — intervention group
Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 60
Study 24972754 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive training (MCT)
Number of subjects: 50
Study 24972754 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (Control)
Number of subjects: 50
Study 22853619 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Traditional Chinese Medicine (TCM) for four cycles, administered every 3 weeks.
Number of subjects: 480
Study 22853619 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (placebo) for four cycles, administered every 3 weeks.
Number of subjects: 480
Study 20698866 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 44
Study 20698866 — intervention group
Group type: COMPARATOR
Intervention: 2% plain lidocaine
Number of subjects: 44
Study 17971598 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) 30 Gy; 2 Gy daily fractions
Number of subjects: 106
Study 17971598 — intervention group
Group type: COMPARATOR
Intervention: No PCI
Number of subjects: 106
Study 15830302 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education program (four sessions)
Number of subjects: 145
Study 15830302 — intervention group
Group type: COMPARATOR
Intervention: Control group (education after one year)
Number of subjects: 145
Study 11976209 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) pretreatment prior to stress
Number of subjects: 0
Study 11976209 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9696640 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg orally twice daily
Number of subjects: 703
Study 9696640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 703
Study 7928814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil (20 mg/kg/day bd)
Number of subjects: 361
Study 7928814 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate (13.3 mg/kg/day tid)
Number of subjects: 361
Study 7928814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil
Number of subjects: 361
Study 7928814 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate
Number of subjects: 361